Yes, blood tests can help stage disease progression in dementia and other neurodegenerative conditions, but they work differently than you might expect. Rather than serving as standalone diagnostic tools, blood biomarker tests reveal the underlying pathology—such as amyloid-beta, phosphorylated tau, and other protein changes—that correlate with disease stage. For example, a patient showing elevated phosphorylated tau-181 in blood may be in early cognitive decline or preclinical stages of Alzheimer’s disease, helping clinicians confirm or refine a diagnosis that clinical exams alone cannot establish with certainty. However, blood tests are most powerful when combined with cognitive assessments, brain imaging, and clinical history.
A single elevated biomarker does not automatically determine a person’s disease stage or prognosis. The relationship between blood biomarkers and clinical symptoms exists, but the timeline and severity vary significantly between individuals. Some people with biomarker evidence of pathology remain cognitively normal for years, while others decline more rapidly despite similar biomarker levels. Blood tests represent a significant advance because they are far less invasive than cerebrospinal fluid sampling and more accessible than PET imaging, yet they provide similar biological insights. This shift is changing how neurologists and primary care physicians approach early detection and disease monitoring in memory loss and neurological decline.
Table of Contents
- What Blood Biomarkers Reveal About Neurological Disease Stages
- The Gap Between Biomarkers and Clinical Symptoms
- Blood Tests for Tracking Disease Progression Over Time
- When and How to Use Blood Tests in Clinical Practice
- Limitations and Misinterpretation Risks
- Combining Blood Tests with Imaging and Cognitive Testing
- Current and Emerging Blood Biomarkers for Staging
What Blood Biomarkers Reveal About Neurological Disease Stages
Blood biomarkers measure proteins and fragments that accumulate or change as the brain undergoes pathological changes. The most studied markers in dementia are phosphorylated tau (P-tau181, P-tau217), amyloid-beta-42, and neurofilament light chain (NfL). Each reflects different aspects of brain damage: amyloid and tau accumulation signal the hallmark pathology of Alzheimer’s disease, while neurofilament light chain indicates general neuronal damage regardless of cause. A patient with cognitive complaints but normal cognition on testing might show elevated phosphorylated tau, suggesting preclinical disease—the stage before memory problems appear but after pathological changes have begun. The ability to detect these stages in blood has proven valuable for research and increasingly for clinical practice.
Before blood biomarker tests became available, clinicians could only identify disease when cognitive symptoms were obvious. Now, abnormal biomarkers can appear 10–20 years before noticeable cognitive decline. However, detecting a biomarker abnormality does not mean a person will definitely develop symptoms or decline at a predictable rate. This is a crucial limitation: many biomarker-positive individuals never develop dementia during their lifetime. In clinical settings, blood tests are most useful when there is already concern about cognitive change. A patient with mild memory complaints, normal cognitive testing, and elevated phosphorylated tau may warrant closer monitoring or further imaging, whereas a cognitively normal patient with incidental biomarker elevation might simply be observed.
The Gap Between Biomarkers and Clinical Symptoms
A major limitation of blood biomarkers is that they do not always correlate tightly with how a person actually functions. Someone can have high amyloid levels and remain fully independent, while another person with lower biomarker levels may struggle with memory and daily tasks. This disconnect occurs because cognitive reserve—education, mental stimulation, brain size, and genetic factors—protects some individuals from the cognitive effects of pathology for many years. A highly educated person with strong cognitive reserve might tolerate substantial amyloid and tau burden without significant cognitive impairment, whereas someone with lower reserve might show symptoms at lower biomarker levels. This unpredictability is why neurologists warn against overstating what biomarkers mean for an individual patient.
Ordering a blood test because someone is worried about forgetting names or misplacing keys without any other cognitive concerns could lead to unnecessary anxiety if that test shows elevated markers. In contrast, a person with documented cognitive decline and an MRI showing brain atrophy has more actionable information even if biomarkers are ordered. Additionally, blood biomarkers can persist at abnormal levels for years without corresponding cognitive decline. A 65-year-old with elevated phosphorylated tau might have stable cognitive function for a decade or more. The temporal relationship between biomarker changes and cognitive decline varies widely and remains difficult to predict at the individual level.
Blood Tests for Tracking Disease Progression Over Time
For people already diagnosed with mild cognitive impairment or dementia, serial blood tests—measurements taken over months or years—can help track whether disease is progressing. If neurofilament light chain levels are rising over successive tests, this suggests ongoing neuronal damage and potentially faster decline. If levels remain stable, the disease may be progressing more slowly. For someone on a disease-modifying treatment like aducanumab or lecanemab, blood biomarkers can provide evidence of whether the treatment is slowing pathological changes. An example: a 72-year-old with mild cognitive impairment starts on a monoclonal antibody targeting amyloid.
Blood tests at baseline and 6 months later show a decline in amyloid levels and stable or slightly declining neurofilament levels, suggesting the treatment is reducing amyloid burden and slowing neuronal damage. This objective biomarker data complements cognitive testing and helps the clinician and patient make informed decisions about continuing or modifying treatment. However, blood tests do not replace cognitive assessment or neuropsychological testing as measures of how well someone is functioning. Slowing biomarker changes means slowing pathology, not necessarily slowing cognitive decline in ways the patient will notice. A person whose biomarkers stabilize might still experience gradual functional decline, and conversely, someone with worsening biomarkers might report stable daily function for several months.
When and How to Use Blood Tests in Clinical Practice
Blood biomarkers are most helpful in specific clinical scenarios: when cognitive testing is borderline or inconclusive, when a primary care doctor suspects mild cognitive impairment but wants specialist confirmation before referral, or when someone is enrolled in a research study or treatment trial. They are not recommended as population screening tools for cognitively normal individuals without symptoms or family history of early-onset dementia, because the positive predictive value is too low—most people with elevated biomarkers never develop symptoms. The practical workflow differs from traditional biomarker tests. A person with memory concerns first receives cognitive testing and often neuroimaging (MRI or PET). If cognitive testing is inconclusive, a blood test can provide supporting evidence for or against a diagnosis.
If cognitive testing clearly shows impairment and imaging shows atrophy, blood tests add information about the underlying pathology but rarely change the diagnosis. The trade-off is that blood tests are quick and accessible but cannot replace the clinical interview, cognitive exam, and imaging that form the foundation of diagnosis. Insurance coverage for blood biomarker tests varies. Medicare and many private insurers now cover phosphorylated tau tests when ordered by a neurologist or specialized memory center, but coverage for neurofilament light chain or amyloid-beta tests remains inconsistent. Patients should check with their insurance before testing to understand costs.
Limitations and Misinterpretation Risks
One underappreciated limitation is that blood biomarkers reflect group averages and research findings, not guaranteed individual outcomes. Studies show that elevated phosphorylated tau is associated with higher risk of cognitive decline, but the effect sizes vary. Some people with high markers have slow decline or no decline; others decline rapidly. This means a positive blood test should never be presented to a patient as a definitive prediction of their future cognitive trajectory. Another risk is overdiagnosis of mild cognitive impairment or dementia in older adults who are actually experiencing normal aging.
Cognitive testing can be subjective, and a mildly abnormal result combined with elevated biomarkers may lead to a diagnosis that increases anxiety without changing management. Additionally, blood tests are not standardized across all laboratories, and cutoffs for “abnormal” differ depending on the assay and vendor. A test result of 40 pg/mL for phosphorylated tau might be normal at one lab and abnormal at another, creating confusion and requiring careful interpretation by an experienced clinician. Patients should be wary of direct-to-consumer blood biomarker testing marketed as brain health screening. These tests may be accurate in detecting biomarkers, but without clinical context, cognitive assessment, and expert interpretation, a result saying “elevated amyloid” can cause unnecessary worry and lead to inappropriate interventions.
Combining Blood Tests with Imaging and Cognitive Testing
The strongest diagnostic approach combines blood biomarkers with cognitive testing and structural or molecular brain imaging. A person with memory complaints, borderline cognitive testing, and both elevated biomarkers and amyloid positivity on PET imaging has strong evidence of underlying Alzheimer’s pathology and earlier disease stage.
In contrast, someone with similar biomarker results but normal cognitive testing and negative PET imaging likely represents preclinical disease with slower progression risk. Many specialized memory centers now use this integrated approach as standard care. Blood tests reduce the need for PET scans in some situations—for instance, if biomarkers are negative in someone with borderline cognitive symptoms, further amyloid imaging may not be needed, and other causes of cognitive impairment can be explored instead.
Current and Emerging Blood Biomarkers for Staging
Beyond phosphorylated tau and amyloid-beta, newer blood biomarkers are being studied to improve disease staging. Phosphorylated tau-217 and phosphorylated tau-181 show promise for differentiating Alzheimer’s from other dementias better than traditional markers. Plasma glial fibrillary acidic protein (GFAP) and phosphorylated forms of ubiquitin measured in blood correlate with astrocyte activation and microglial response, reflecting broader neuroinflammation.
These emerging markers may eventually provide more granular staging or predictions of disease trajectory. Research published in major neurology journals has shown that combinations of multiple biomarkers—a “panel” approach—predict cognitive decline more accurately than single markers alone. However, these tests are still primarily used in research settings and specialist centers, not routine primary care. As more data accumulates on how these combinations predict outcomes, their clinical utility for staging and prognosis will likely improve, but individual variability will remain substantial.
- —
